Discovery of the Clinical Candidate CYRS1542: A Potent, Orally Available, & Well-Tolerated GSPT1 Molecular Glue Degrader Guided by Neuroendocrine Cancer Sensitivity
- Analyzing how CYRS1542 exhibits favorable ADME/PK properties with no apparent DDI liabilities and demonstrates potent antitumor activity in preclinical CDX and PDX models
- Exploring how neuroendocrine features, including high CRBN expression, are associated with increased sensitivity to CYRS1542, providing the rationale for focusing clinical development on patients with neuroendocrine cancers (e.g., SCLC, NEPC)
- Evaluating how CYRS1542 showed a broader in vitro therapeutic index and a favorable safety profile in GLP monkey toxicology studies, with no evidence of thrombocytopenia, supporting the initiation of the first-in-human study in December 2025